The Worldwide Market for Liquid Biopsy, 6th Edition - ResearchAndMarkets.com

2024-01-22
Business Wire
DUBLIN--(BUSINESS WIRE)--The "Worldwide Market for Liquid Biopsy, 6th Edition" report has been added to ResearchAndMarkets.com's offering.
'Worldwide Market for Liquid Biopsy, 6th Edition'
Liquid biopsies have emerged as a minimally invasive diagnostic tool, analyzing tumor-derived materials circulating in biological fluids to offer valuable information for cancer diagnosis, treatment, and monitoring. While tissue biopsies and imaging techniques remain standard in solid tumor diagnosis, liquid biopsies present an alternative or complementary approach, addressing some of the limitations and risks associated with traditional methods.
The liquid biopsy market is experiencing significant changes, and The Worldwide Market for Liquid Biopsy, 6th Edition provides an in-depth assessment of the market opportunity from 2023 to 2028. It covers various aspects, including market segmentation by region, different types of liquid biopsy (CTC-based, ctDNA-based, EV and Exosome-based, Multi-Analyte-based, and Other Analytes), and cancer types.
Key applications of liquid biopsy testing in clinical oncology include:
1. Early Detection and Diagnosis/Screening:
Identifying cancer at an early stage.
2. Alternative Testing Method:
When tissue biopsy is challenging or impossible.
When the primary site of metastatic disease is unknown.
3. Therapy Personalization and Monitoring:
Molecular characterization to select optimal therapy.
Monitoring treatment efficacy and adjusting therapy in case of resistance.
4. Disease Monitoring:
Observing disease progression, tumor evolution, residual disease.
Early detection of recurrence.
5. Prognosis of Disease:
Assessing the likely course and outcome of the disease.
Key Market Segments:
By Region:
North America
Europe
Asia
Rest of World
By Type of Liquid Biopsy:
CTC-based Liquid Biopsy
ctDNA-based Liquid Biopsy
EV and Exosome-based Liquid Biopsy
Multi-Analyte-based Liquid Biopsy
Other Analytes Liquid Biopsy
By Type of Cancer:
Breast
Lung
Colorectal
Ovarian
Prostate
Pan-Cancer
Other Cancers
R&D and Selected Tests:
Selected ctDNA-based Liquid Biopsy Tests in Development
Selected CTC-based Liquid Biopsy Tests in 2023
Selected Liquid Biopsy Tests Assessing Multiple Analytes in 2023
The growing acceptance of liquid biopsy, even during the COVID-19 pandemic, underscores its increasing significance in clinical diagnostics. Liquid biopsy's potential in combination with other technologies further contributes to its expanding applications and market growth.
Key Topics Covered:
Chapter One: Executive Summary
Liquid Biopsy Technologies
Industry Structure
Liquid Biopsy Market Revenues and Forecast
Chapter Two: Liquid Biopsy Technologies
Current Major Liquid Biopsy Technologies
Chapter Three: Circulating Tumor DNA (Ctdna) Liquid Biopsy
Advantages and Limitations of Ctdna in Liquid Biopsy
Current Ctdna-based Liquid Biopsy Tests
Cellmax Life
Circulogene
Diacarta
Foundation Medicine (Roche)
Guardant Health
Inivata (Neogenomics)
Lunglife AI
Oncodna
Personal Genomic Diagnostics (Labcorp)
Resolution Biosciences (Exact Sciences)
Sysmex-Inostics
Tempus
Ctdna-based Liquid Biopsy Tests in Development
Grail
Chapter Four: Circulating Tumor Cells (Ctcs) Liquid Biopsy
Challenges in the Development of Ctc-based Liquid Biopsy Tests
Ctc-based Liquid Biopsy Tests
Angle
Cellmax Life
Lunglife AI
Selected Ctc-based Liquid Biopsy Tests in Development
Chapter Five: Extracellular Vesicles and Other Liquid Biopsy
Liquid Biopsy Tests Based on Extracellular Vesicles / Other Analysts
Aspira Women's Health (Formerly Vermillion)
Hologic
Mdxhealth
Extracellular Vesicle/Other Analyst-based Liquid Biopsy Tests in Development
Circulogene
Oncocyte
Resolution Biosciences (Exact Sciences)
Chapter Six: Multi-Analyst Liquid Biopsy Tests
Liquid Biopsy Tests Based on Multiple Analysts
Foundation Medicine (Roche)
Lunglife AI
Oncodna
Multiple Analyst-based Liquid Biopsy Tests in Development
Grail
Lunglife AI
Chapter Seven: Liquid Biopsy Tests for Research Use Only
Liquid Biopsy Tests for Research Use Only
Diacarta
Guardant Health
Chapter Eight: Liquid Biopsy Industry Analysis
Tiers of Competition
Competitive Factors
Significant Market Trends
Increasing Global Life Expectancy
New Liquid Biopsy Products
Increasing Accessibility of Genetic Testing
Regulatory Hurdles
Third-Party Payor Coverage
Demonstrated Clinical Utility
Incidence Rates of Specific Cancers
Competitors No Longer in the Liquid Biopsy Market
Chapter Nine: Liquid Biopsy Market
Market Overview
Market Forecast
Chapter Ten: Market by Analyst
Circulating Tumor DNA
Circulating Tumor Cells
Extracellular Vesicles and Other Analysts
Chapter Eleven: Market by Application
Therapy Guidance and Monitoring
Diagnosis/Screening
Disease Prognosis
Chapter Twelve: Market by Cancer Type
Other Cancers
Pan-Cancer Tests
Chapter Thirteen: Company Profiles
Aspira Women's Health
Biocept, Inc. (closed)
Cellmax Life
Circulogene
Gilupi Gmbh
Grail (Illumina)
Hologic
Lunglife AI (Formerly Cynvenio Biosystems)
Cell-Free DNA Technologies
Exosome And Mirna Technologies
Tempus
For more information about this report visit https://www.researchandmarkets.com/r/7c9qdk
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。